

**Fiscal Year 2026 Congressionally Directed Medical Research Programs
Amyotrophic Lateral Sclerosis Research Program (ALSRP)
Reference Table of Award Mechanisms and Submission Requirements**

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Clinical Outcomes and Biomarkers Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT942526ALSRPCOBA</p>	<p>Independent investigators at all academic levels, or equivalent</p>	<ul style="list-style-type: none"> • Supports the development and validation of clinical outcomes and/or biomarkers to improve clinical trials in ALS. <ul style="list-style-type: none"> ○ Clinical outcome studies may include clinician-, observer-, or patient-reported, and/or performance outcome measures for ALS. ○ Clinical biomarkers should be specific for ALS; studies may include but are not limited to susceptibility/risk, diagnostic, phenotypic conversion, monitoring, prognostic, predictive, response or safety biomarkers. • Applications should include strong data sharing plans. • Applications cannot support interventional clinical trials. However, applications may propose non-interventional studies prospectively collecting biospecimens and/or data, including clinical research studies that complement existing trials. • Pre-applications and applications must include a community partner (e.g., patient/care partner, community-based organization consultant) who will provide advice and consultation during study design and throughout study planning and implementation. • Submission of a Preproposal is required; full application submission is by invitation only. • Clinical trials are not allowed. 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$1 million (M) for total costs.* • The maximum period of performance is 3 years. 	<p>Pre-Application (Preproposal): June 24, 2026 5:00 p.m. Eastern time</p> <p>Application: September 30, 2026 11:59 p.m. Eastern time</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Pilot Clinical Trial Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT942526ALSRPPCTA</p>	<p>Independent investigators at all academic levels, or equivalent</p>	<ul style="list-style-type: none"> • Supports the rapid implementation of early-stage clinical trials with potential to significantly impact treatment or symptom management of ALS. • Applications must address one focus area: <ul style="list-style-type: none"> ◦ Biomarker-Driven Interventions: Disease-modifying interventions with mechanism-specific predictive and/or mechanism-specific pharmacodynamic biomarkers. <p>OR</p> <ul style="list-style-type: none"> ◦ Clinical Care: Improving aspects of clinical care and symptom management strategies. <ul style="list-style-type: none"> • Applications must include a clinical trial(s) that addresses more than just safety of the intervention. Projects should also be designed to assess therapeutic efficacy, biological effects, and/or clinical outcomes, and may range from phase 1 to small-scale phase 2 trials. • Applications should include research projects that aim to de-risk and inform the design of more advanced trials. • Applications proposing a therapeutic intervention (e.g., drug, biologic, and/or device) must incorporate biomarkers specific to the intervention into the trial design. • Pre-applications and applications must include a community collaborator (e.g., patient/care partner, community-based organization consultant) who will provide advice and consultation during study design and throughout study planning and implementation. • Submission of a Preproposal is required; full application submission is by invitation only. 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$2.8M for total costs.* • The maximum period of performance is 3 years. 	<p>Pre-Application (Preproposal): June 24, 2026 5:00 p.m. Eastern time</p> <p>Application: September 30, 2026 11:59 p.m. Eastern time</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Therapeutic Development Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT942526ALSRPTDA</p>	<p>Independent investigators at all academic levels, or equivalent</p>	<ul style="list-style-type: none"> • Supports research ranging from preclinical validation of therapeutic leads through Investigational New Drug-enabling studies of therapeutics for ALS. • Applications must confirm that the lead compound(s) is already in hand and provide proof-of-concept efficacy data in at least one appropriate preclinical model system of ALS. • Applications require preliminary data, including therapeutic efficacy data in at least one relevant preclinical ALS model system. • Applications should include <i>mechanism-specific</i> predictive/cohort-selective, target engagement, and pharmacodynamic biomarker development, in parallel to the main therapeutic effort. For studies using mechanism-specific biomarkers that are already available or currently in development, applications must describe how the existing biomarkers will improve trial design, patient selection, and efficiency or interpretation of the proposed ALS therapeutic approach. • <i>Submission of a Preproposal is required; full application submission is by invitation only.</i> • <i>Clinical trials are not allowed.</i> 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$2.0M for total costs.* • The maximum period of performance is 3 years. 	<p>Pre-Application (Preproposal): June 24, 2026 5:00 p.m. Eastern time</p> <p>Application: September 30, 2026 11:59 p.m. Eastern time</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Therapeutic Idea Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT942526ALSRTIA</p>	<p>Independent investigators at all academic levels, or equivalent</p>	<ul style="list-style-type: none"> • Supports new, innovative, high-risk, high-gain hypothesis-driven ideas aimed at ALS drug or therapy discovery. • Applications that propose incremental advancement of ongoing research will not meet the intent of the award mechanism. • Applications do not require preliminary data; however, rationale and experimental feasibility are important. The strength of the application should rely on the approach. • Applications focusing primarily on ALS pathophysiology without development of a therapy will not be considered. • Applications must include rational development of a biomarker(s) to measure biological effects of the study compound or modality for eventual clinical trials. • Submission of a Preproposal is required; full application submission is by invitation only. • Clinical trials are not allowed. 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$840,000 for total costs.* • The maximum period of performance is 2 years. 	<p>Pre-Application (Preproposal): June 24, 2026 5:00 p.m. Eastern time</p> <p>Application: September 30, 2026 11:59 p.m. Eastern time</p>

*Total costs include direct and indirect costs.